Albert D. Mason Inc’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.93M Buy
25,727
+140
+0.5% +$21.5K 2.54% 4
2025
Q4
$3.53M Buy
25,587
+88
+0.3% +$11.5K 2.32% 3
2025
Q3
$3.27M Buy
25,499
+1,135
+5% +$138K 2.13% 4
2025
Q2
$2.95M Sell
24,364
-1,664
-6% -$188K 2.13% 4
2025
Q1
$2.9M Buy
26,028
+12,774
+96% +$1.36M 1.97% 4
2024
Q4
$1.29M Sell
13,254
-223
-2% -$23.8K 0.86% 47
2024
Q3
$1.55M Sell
13,477
-74
-0.5% -$8.4K 0.99% 38
2024
Q2
$1.44M Buy
13,551
+63
+0.5% +$6.32K 0.98% 40
2024
Q1
$1.3M Buy
13,488
+17
+0.1% +$1.74K 0.81% 53
2023
Q4
$1.36M Sell
13,471
-30
-0.2% -$2.9K 0.9% 40
2023
Q3
$1.38M Sell
13,501
-1,480
-10% -$150K 1% 30
2023
Q2
$1.51M Sell
14,981
-437
-3% -$43.7K 1.04% 28
2023
Q1
$1.42M Sell
15,418
-64
-0.4% -$5.59K 0.98% 34
2022
Q4
$1.41M Sell
15,482
-23
-0.1% -$1.94K 1% 34
2022
Q3
$1.18M Buy
15,505
+90
+0.6% +$7.46K 0.94% 42
2022
Q2
$1.3M Buy
15,415
+17
+0.1% +$1.49K 0.97% 31
2022
Q1
$1.35M Sell
15,398
-294
-2% -$25.5K 0.87% 42
2021
Q4
$1.37M Buy
15,692
+2,494
+19% +$207K 0.82% 46
2021
Q3
$1.08M Buy
13,198
+38
+0.3% +$3.42K 0.7% 66
2021
Q2
$1.2M Sell
13,160
-430
-3% -$38.3K 0.74% 61
2021
Q1
$1.16M Sell
13,590
-135
-1% -$12.1K 0.76% 58
2020
Q4
$1.3M Buy
13,725
+146
+1% +$12.8K 0.9% 47
2020
Q3
$1.18M Buy
13,579
+225
+2% +$19.5K 0.97% 40
2020
Q2
$1.17M Sell
13,354
-70
-0.5% -$6.04K 0.98% 41
2020
Q1
$1.11M Buy
13,424
+45
+0.3% +$4.01K 1.11% 34
2019
Q4
$1.27M Buy
13,379
+225
+2% +$20.2K 0.9% 46
2019
Q3
$1.14M Buy
13,154
+45
+0.3% +$4.04K 0.86% 51
2019
Q2
$1.2M Sell
13,109
-1,599
-11% -$135K 0.9% 46
2019
Q1
$1.27M Buy
14,708
+156
+1% +$12.5K 0.93% 45
2018
Q4
$1.12M Sell
14,552
-83
-0.6% -$6.46K 0.91% 43
2018
Q3
$1.13M Buy
14,635
+2,807
+24% +$208K 0.77% 59
2018
Q2
$801K Buy
11,828
+2,678
+29% +$185K 0.58% 80
2018
Q1
$663K Sell
9,150
-39
-0.4% -$2.97K 0.5% 83
2017
Q4
$691K Buy
9,189
+28
+0.3% +$2.11K 0.52% 87
2017
Q3
$705K Sell
9,161
-7,254
-44% -$548K 0.57% 81
2017
Q2
$1.23M Hold
16,415
1.03% 38
2017
Q1
$1.09M Sell
16,415
-11
-0.1% -$733 0.93% 42
2016
Q4
$1.07M Sell
16,426
-23,792
-59% -$1.54M 0.94% 44
2016
Q3
$2.85M Buy
40,218
+18,904
+89% +$1.38M 0.92% 44
2016
Q2
$1.58M Buy
21,314
+71
+0.3% +$4.91K 0.92% 42
2016
Q1
$1.38M Hold
21,243
0.84% 46
2015
Q4
$1.64M Sell
21,243
-538
-2% -$42.7K 1.07% 37
2015
Q3
$1.79M Buy
21,781
+6,101
+39% +$543K 1.11% 38
2015
Q2
$1.38M Sell
15,680
-55,173
-78% -$5.06M 0.75% 53
2015
Q1
$6.26M Sell
70,853
-13,266
-16% -$1.18M 1.3% 22
2014
Q4
$6.98M Buy
84,119
+246
+0.3% +$20.4K 1.39% 22
2014
Q3
$7.07M Buy
83,873
+547
+0.7% +$44.3K 1.39% 23
2014
Q2
$6.76M Sell
83,326
-23,246
-22% -$1.83M 1.23% 30
2014
Q1
$8.12M Sell
106,572
-13,058
-11% -$952K 1.59% 17
2013
Q4
$8.62M Sell
119,630
-14,156
-11% -$984K 1.7% 12
2013
Q3
$9.2M Sell
133,786
-865
-0.6% -$57.2K 1.93% 6
2013
Q2
$8.53M Buy
+134,651
New +$8.76M 1.89% 10

Other funds holding NVS

Albert D. Mason Inc's NVS Position: Q1 2026 in Review

Albert D. Mason Inc increased its Novartis (NVS) stake by 0.55% in Q1 2026, buying an estimated $21.5K and bringing the position to 25,727 shares worth $3.93M. The position accounts for 2.54% of the portfolio, ranked #4.

Albert D. Mason Inc first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $9.2M in Q3 2013. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Albert D. Mason Inc held 25,727 shares of Novartis worth $3.93M as of Q1 2026.
  • Albert D. Mason Inc bought 140 Novartis shares in Q1 2026, an estimated $21.5K.
  • Novartis made up 2.54% of Albert D. Mason Inc's portfolio in Q1 2026, its #4 holding.
  • Albert D. Mason Inc first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Albert D. Mason Inc's Novartis position peaked at $9.2M in Q3 2013.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Albert D. Mason Inc's 13F filing for Q1 2026, filed 15 Apr 2026.